title: [Cooperative study of postoperative long-term adjuvant therapy of breast cancer. First study of a series--comparative study between postoperative tegafur administration and no adjuvant chemotherapy].
abstract: A prospective randomized study was performed in 22 institutions from July 1978, to evaluate the efficiency of long-term adjuvant chemotherapy with tegafur alone for primary breast cancer. Five hundred and eighty-seven eligible patients, classified into T1a, T2a, T3a, N0, N1a, N1b, and M0 were divided into two groups: Group A, radical mastectomy receiving no adjuvant chemotherapy; and Group B, radical mastectomy followed by 4 courses of adjuvant chemotherapy, each one consisting of daily administration of tegafur 600 mg p.o. for 8 weeks and 4 weeks rest. At the 66th month of median follow up time, there were no differences between the two groups on 5 year cumulative survival and disease free survival rate. In subgroup patients who have histologically 1-3 axillary involvements, there seemed to be a more meaningful prolongation of the disease-free interval in group B than in group A (logrank test; p = 0.11 generalized Wilcoxon test; p = 0.13).
authors.affiliation: Dept. of Surgery, Center for Adult Diseases, Osaka.
authors.forename: T
authors.initials: T
authors.lastname: Terasawa
authors.forename: G
authors.initials: G
authors.lastname: Kousaki
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Senoo
authors.forename: T
authors.initials: T
authors.lastname: Taguchi
authors.forename: Z
authors.initials: Z
authors.lastname: Iwasa
authors.forename: J
authors.initials: J
authors.lastname: Utsunomiya
authors.forename: K
authors.initials: K
authors.lastname: Okajima
authors.forename: E
authors.initials: E
authors.lastname: Okamoto
authors.forename: T
authors.initials: T
authors.lastname: Kawahara
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008408:Mastectomy; D008875:Middle Aged; D011182:Postoperative Care; D011446:Prospective Studies; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D005641:Tegafur